
Zhitong Finance App News, Collie Pharmaceutical-B (01672) issued an announcement. Clery recently showcased the oral small molecule GIPR agonist ASC48, GLP-1R/GIPR dual-target oral small molecule ASC30_48 FDC (fixed dose combination preparation of ASC30 and ASC48), and long-term administration of GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 at ObesityWeek® 2026 held in Washington, D.C., from November 14 to 17, 2026 Results of previous studies.
The two posters presented the in vitro activity and oral pharmacokinetics (PK) of ASC48, weight loss data for ASC30_48 FDC, and the long-term pharmacokinetics, insulin secretion, and weight loss activities of ASC37.
ASC30_48 FDC is an oral small molecule compound developed independently by Goli. It targets GLP-1R and GIPR, and is expected to be the first first-in-class (first-in-class) oral treatment for obesity and other metabolic diseases, once a day, one tablet at a time. These pre-clinical data on receptor activity, oral pharmacokinetics, and weight loss support advancing the project into further clinical development.
ASC37 was developed using Goli's proprietary structure-based AI-assisted drug discovery (AISBDD) and ultra-long-acting drug development platform (ULAP) technology. By combining the agonistic activity of GLP-1R, GIPR, and GCGR with long-acting pharmacokinetic characteristics, ASC37 aims to provide a potential treatment option for long-term weight management with monthly to quarterly subcutaneous injections (injection volume not more than 1 ml). Preliminary preclinical data suggest that ASC37 has shown good efficacy in weight loss and appetite suppression, and has good pharmacokinetic properties, supporting its promise to be the best-in-class (best-in-class) treatment candidate. Its pharmacokinetics, safety and efficacy will be further evaluated through clinical trials.